cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Zynerba Pharmaceuticals Inc
21 own
49 watching
Current Price
$0.67
$0.05
(7.29%)
logo-zyne
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
31.53M
52-Week High
52-Week High
2.94
52-Week Low
52-Week Low
0.49
Average Volume
Average Volume
1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization31.53M
icon52-Week High2.94
icon52-Week Low0.49
iconAverage Volume1M
iconDividend Yield--
iconP/E Ratio--
What does the Zynerba Pharmaceuticals Inc do?
Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.
Read More
How much money does Zynerba Pharmaceuticals Inc make?
News & Events about Zynerba Pharmaceuticals Inc.
Globe Newswire
21days ago
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the pathogenesis of Fragile X syndrome (FXS) Cannabidiol may help restore the function of the ECS in FXS patients according to review of data Consistent with the ...
Globe Newswire
1month ago
RECONNECT initial screening visits are being adversely impacted by environmental factors, such as the Tripledemic (high rates of RSV, influenza and COVID-19); topline results now expected first half of 2024 Cash runway extended to mid-year 2024 due to prioritization of resources on the completion of...
Globe Newswire
2 months ago
Study finds patients with Fragile X who have a highly methylated FMR1 gene that were treated with Zygel showed a significant reduction in behavioral symptoms compared to those treated with placebo Topline results from follow-on RECONNECT confirmatory pivotal Phase 3 trial of Zygel in patients with a...
Globe Newswire
3 months ago
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 2022 National Organization for ...
Globe Newswire
4 months ago
INSPIRE trial in 22q achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments, with excellent tolerability profileDEVON, Pa., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative ...
Frequently Asked Questions
Frequently Asked Questions
What is Zynerba Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Zynerba Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Zynerba Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Zynerba Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Zynerba Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Zynerba Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Zynerba Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Zynerba Pharmaceuticals Inc?
plus_minus_icon
What percentage is Zynerba Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Zynerba Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.67
$0.05
(7.29%)
logo-zyne
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00